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Antimicrobial prescribing in respiratory tract infection is generally empirical. Agents that do not eradicate the key 
bacterial respiratory pathogens (Streptococcus pneurnoniae, Haemophilus influenzae, and Moraxella catarrhalis) 
provide suboptimal therapy. A recent paper developed by a multidisciplinary, multinational group presented a 
consensus on the principles that should underpin appropriate antimicrobial prescribing. In summary, in order to 
ensure clinical success and minimize the threat of resistance, empirical therapy should avoid unnecessary and 
inappropriate use of antimicrobials, deliver the right agent at the right dose and duration, and rapidly eradicate the 
pathogen at the site of infection. Accurate diagnosis is essential to ensure that only bacterial infections are treated 
with antibacterial agents.The application of pharmacokinetic/pharmacodynamic (PK/PD) principles to both new and 
existing antimicrobials allows the prediction of bacteriologic efficacy. Applying these principles when prescribing 
therapy can help in reducing the potential for the selection and spread of resistance. Local resistance patterns and 
the bacteriologic/clinical impact of resistance should also be considered. The use of antimicrobials with optimal 
PK/PD characteristics may be more cost-effective than allowing the possibility of resistance-induced failure. 
Changing prescribing habits without taking all these factors into account may increase the incidence of unfavorable 
patient outcomes and the cost of treatment, with more referrals and hospitalizations. Changes in prescribing habits 
should be considered carefully, to avoid unintended negative consequences. It is the responsibility of physicians to 
ensure that each prescription is necessary and will maximize the potential for clinical cure, but there is also a 
collective responsibility to sustain the diversity of antimicrobial therapy via appropriate formularies, guidelines and 
licensing, reduced over-the-counter availability, and continued research and development through academia and 
industry. To maximize clinical cure and minimize the emergence and spread of resistance, antimicrobial prescribing 
should maximize bacterial eradication, and clinical drug evaluation needs to be brought into line with this need. 
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INTRODUCTION 
The global emergence of bacterial resistance (parti- 
cularly multiresistance) to many available antimicrobials 
presents a significant challenge. In order to meet this 
challenge, we require a radical rethink of the way 
in which antimicrobials are used. When prescribing 
antimicrobials, we need to consider not only the impact 
on the patient in terms of achieving clinical cure and 
minimizing adverse reactions, but also the ecological 
impact on the wider community in terms of the potential 
to drive resistance. The physician, therefore, has a 
responsibility to the patient (individual responsibility), 
and a collective (or community) responsibility to sustain 
bacterial susceptibility. Consequently, a balance must be 
struck, which we think of in terms of the ‘appropriate’ 
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use of antimicrobials. This paper examines the impact of 
antimicrobial prescribing on outcomes and resistance, 
and discusses how we can work towards achieving 
appropriate prescribing through the application of 
pharmacokinetic/pharmacodynamic (PK/PD) principles 
(see M. R. Jacobs and R. Dagan, this issue) in order 
to achieve bacterial eradication (see J. Garau and R. 
Dagan, this issue). 
WHAT IS APPROPRIATE PRESCRIBING? 
In order to meet the dual requirements of maximizing 
cure and minimizing resistance, each antimicrobial 
prescription should be both necessary and appropriate. 
First and foremost, antimicrobials should be used 
only to treat bacterial infection. This is often not stressed 
enough (or at all) in published guidelines, reflecting the 
difficulty of diagnosing bacterial infection in clinical 
practice. There are currently no rapid and accurate 
diagnostic tests that can determine whether a patient 
has a bacterial infection. Thus, antimicrobial prescribing 
is usually empirical-almost exclusively so in the com- 
munity setting. Unnecessary antimicrobial prescribing is 
not a neutral activity, as there are a number of negative 
consequences: 
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1. Exposing patients to the risk of side effects without 
any clinical benefit. 
2. The cost of drugs that are not needed and costs 
associated with side effects. 
3. The risk of superinfection. 
4. An increased potential for the development and 
spread of resistance in the bacterial flora. 
Appropriate prescribing means maximizing the potential 
for clinical cure, and this can only be achieved by maxi- 
mizing the potential for bacterial eradication.la2 As most 
antimicrobial use is empirical, the choice of agent needs 
to reflect both the likely etiology and local antimicrobial 
resistance prevalences. Failure to prescribe appropriately 
leads to clinical failure and drives the development and 
spread of resistance (see J. Garau, this issue). 
LIMITATIONS OF GUIDELINES IN DRIVING 
PRESCRIBING CHANGE 
Appropriate prescribing can be encouraged by the 
definition of appropriate formularies, guidelines, and 
licensing; reducing the availability of over-the-counter 
antimicrobials (a major issue in some areas of the world); 
and continued drug development to address increasing 
antimicrobial resistance. 
One of the primary mechanisms employed to bring 
about prescribing change is the introduction of guide- 
lines. Numerous guidelines are available for antimicrobial 
prescribing in respiratory tract infection. However, they 
are not without limitations. Various interested parties 
may have had input into guidelines, such as groups of 
opinion leaders, government licensing agencies, health 
management organizations, and the pharmaceutical 
industry, who may have different or conflicting objectives. 
Unfortunately, it is not often clear which underlying 
principles have led to the formulation of guidelines, and 
this may obscure the fact that they may be applicable 
only in certain clinical situations, indications or locations. 
One of the main problems with guidelines is that 
they are often highly complex, and it is difficult for an 
individual physician in a busy clinic to remember 
intricate algorithms. Furthermore, guidelines may vary 
between countries and between professional societies, 
possibly reflecting the ambiguity of the clinical data as 
well as inter-specialty and national differences.3-5 In 
addition, most guidelines fail to consider local patterns 
of resistance or availability of antimicrobials, which are 
essential considerations if prescribers are to fulfill both 
their individual and collective responsibilities. Another 
major drawback is that guidelines are often based on the 
results of non-inferiority studies, using only clinical 
and not bacteriologic endpoints. Finally, guidelines will 
not always be applicable when financial resources are 
limited, a situation that necessitates a balance between 
best practice and costs. 
IMPACT OF PRESCRIBING CHANGE ON 
CLINICAL OUTCOMES AND COSTS 
The publication of guidelines itself does not necessarily 
ensure that prescribing practices become more appro- 
priate. Several studies have examined whether or not 
compliance with guidelines and directives on anti- 
microbial prescribing actually improve patient outcomes, 
alter the prevalence of resistance to antimicrobials, and 
reduce costs. 
In a prospective cohort study, Gleason et al6 
compared medical outcomes and antimicrobial costs in 
immunocompetent outpatients whose treatment for 
community-acquired pneumonia (CAP) was either 
consistent with, or inconsistent with, the American 
Thoracic Society (ATS) guidelines published in 1993.7 
All patient care in this observational study, including the 
choice of antimicrobial, was dictated by the patients’ 
managing physicians. For patients aged 560 years with 
no co-morbidity, antimicrobial costs were reduced three- 
fold when antimicrobial therapy was consistent with the 
guidelines, compared with costs for patients not treated 
according to the guidelines (Table 1). Although there 
was no significant difference in medical outcome, 
patients treated consistently according to the guidelines 
returned to work a median of 1 day earlier. In contrast, 
for patients aged > 60 years or with co-morbidity, whose 
therapy was consistent with the guidelines, there was 
a trend towards increased mortality and an increased 
need, for subsequent hospitalization compared with 
those in whom the guidelines were not followed, and 
at the same time the costs of antimicrobial agents in- 
creased l0-fold.6 
Table 1. Medical outcomes and associated costs in patients treated consistently or not consistently with the American Thoracic Society 
Guideline9 for outpatients with community-acquired pneumonia. Data obtained from Gleason et al6 
Patients 160 years without Patients 260 years or with 
co-morbidity co-morbidity 
Consistent Inconsistent p-value Consistent Inconsistent p-value 
Mortality (%) 0.0 0.0 NA 5.4 0.8 0.06 
Subsequent hospitalization (%) 3.5 5.3 0.32 17.9 8.0 0.09 
Return to work (median days) 7 8 0.04 7 7 0.31 
Total median costs (US$) 5.43 18.51 <0.0001 73.50 7.50 <O.OOl 
NA, not applicable. 
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A non-randomized, prospective study of patients 
hospitalized with CAP found that 81% of patients, 
excluding those admitted to the intensive care unit, were 
treated in accordance with the 1993 ATS guidelines.8 
For patients with non-severe CAP, treatment that 
did not comply with the ATS guidelines was significantly 
associated with increased length of stay in both 
univariate and multivariate analysis. However, for 
patients admitted to the intensive care unit, there was no 
relationship between compliance with ATS guidelines 
and length of stay.* 
In the prospective arm of an observational study, 
deviations from the guidelines occurred most often 
when more aggressive antimicrobial coverage was 
required for suspected aspiration pneumonia.9 In this 
inpatient study, adherence to the ATS7 or Canadian 
Infectious Disease Society/Canadian Thoracic Society lo 
guidelines for treatment of CAP was about 80%. No 
differences in mortality or length of hospitalization were 
found between patients who were treated in accordance 
with these guidelines and those who were not. 
All of the above studies were based on guidelines 
that were published some time ago and may no longer 
be relevant for clinical practice, particularly in areas 
where the prevalence of antimicrobial resistance has 
changed. For example, the ATS guidelines have recently 
been updated,ll and are more strongly evidence-based 
than the previous version. Such revised guidelines, 
which may be more clinically relevant than their 
predecessors, may be found to influence outcome when 
they are formally validated and assessed. 
A recent Australian study provides an example of 
how attempts to enact prescribing change can have 
unintended consequences if they are too narrowly 
focused on achieving one outcome, without taking into 
account the complex relationship between prescribing, 
outcomes, resistance, and costs.12 The study was initiated 
to determine the effect on clinical outcomes and costs 
of an Australian government directive recommending 
that amoxicillin-clavulanate be reserved for cases where 
amoxicillin resistance is known or suspected. Unfortu- 
nately, the directive did not specify alternative agents 
to amoxicillin-clavulanate, such as amoxicillin itself. 
Complete longitudinal records from four general 
practices (22 family physicians) were examined over a 
4-year period. Overall, 15 303 antimicrobial prescriptions 
were provided to 9921 patients over the 4 years. At the 
time, the prevalence of non-susceptible Streptococcus 
pneumoniae was 0.3% for amoxicillin and amoxicillin- 
clavulanate, 21.4% for cefaclor, 16.3% for erythromycin, 
15.9% for tetracycline, and 45.8% for cotrimoxazole.13 
Given the high prevalence of resistance to alternative 
antimicrobial classes, any shift in prescribing away from 
amoxicillin-clavulanate should only have been to 
amoxicillin itself when the presence of p-lactamase- 
producing bacterial pathogens was not suspected. How- 
ever, after the directive, not only did the prescription 
share of amoxicillin-clavulanate decrease from 13.8% 
to 8.6%, but the prescription share of amoxicillin also 
decreased, with a concomitant increase in the pre- 
scription of other antimicrobials, particularly macrolides, 
tetracyclines, and cefaclor. l2 The study documented a 
shift from best practice prescribing, with amoxicillin- 
clavulanate reserved for the more sick patients. Overall, 
clinical management became more conservative, with 
more radiologic and pathologic investigations ordered, 
and hospitalization became more common, although 
whether this was due to an increase in therapeutic 
failure or an increase in the referral rate is unknown 
(Figure 1). I2 Not surprising y, 1 costs also increased, and 
there was a significant relationship between the rate and 
cost of the process of care and patient outcomes, and the 
decrease in amoxicillin-clavulanate prescription share. 
The findings of this study reinforce the view that pre- 
scribing practices, resistance, clinical outcomes and the 
costs of antimicrobial therapy are linked in complex 
ways, and efforts to change one aspect without looking 
at the whole picture may produce unintended altera- 
tions in other aspects. In particular, any directives to 
limit the use of one antimicrobial or combination should 
provide the rationale for choosing alternative agents. 
THE IMPACT OF ANTIMICROBIAL 
PRESCRIBING ON RESISTANCE 
The emergence and development of resistance is not 
well understood, and is likely to be multifactorial.14Very 
few studies have been performed on the effect of 
antimicrobial prescribing change on resistance in the 
community, and no controlled studies are available. 
However, there is some evidence that prescribing 
change can result in significant reductions in resistance 
prevalences. For example, in the early 1990s in Finland, 
increases in the prevalence of erythromycin-resistant 
group A streptococci prompted nationwide recommen- 
dations to reduce the use of macrolides to treat skin and 
20 
18 
sc ‘6- 
5 14- 
; 1% 
II IO- 
&i f 8- 
I5 6- 
4- 
2- 
o- I I I 
Hospitalization Referrals Radiology Pathology Other tests 
n Before letter 0 After letter 
Figure 1. Changes in outcomes as a result of a government 
directive to limit the prescribing of amoxicillin-clavulanate. 
Data from Beilby et al.‘* 
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respiratory tract infections in outpatients. From 1991 to 
1992, the use of macrolides decreased significantly from 
2.4 defined daily doses/1000 population per day to 1.38 
defined daily doses/1000 population per day.15 These 
changes were associated with a significant decrease in 
the prevalence of macrolide resistance from 16.5% to 
8.6% between 1992 and 1996.15 
Although total antimicrobial use is generally 
assumed to be related to the prevalence of resistance, 
the link between prescribing and resistance is likely to 
be much more complex. For example, the co-selection of 
multiresistant strains means that the prescribing of one 
class of agents can select resistance to another class. 
Evidence for this phenomenon comes from studies in 
Iceland on the prevalence of resistant 5’. pneumoniae in 
respiratory tract infections. l&l7 In this study population, 
80% of ,S. pneumoniae strains were multiresistant. 
Following national efforts to reduce antimicrobial usage, 
the consumption of cotrimoxazole and macrolides 
decreased by 30%, although overall consumption of all 
antimicrobials only fell by about 10 %, and penicillin use 
remained relatively stable. 16s7 These changes in pre- 
scribing brought about a reduction not only in the 
prevalence of macrolide and cotrimozaxole resistance, 
but also in penicillin resistance, as the prevalence of 
the multiresistant clone decreased. In fact, an analysis 
of 919 children in this population showed that penicillin 
resistance was twice as likely to be associated with 
the use of erythromycin or cotrimoxazole than with 
P-lactams after three or more courses of treatment.16 
A UK study of the impact of changes in sulfonamide 
prescribing on resistance to these agents in Escherichia 
coli indicates how co-selection could undermine attempts 
to reduce antimicrobial resistance through prescription 
controLl* The licensed indications for cotrimozaxole 
were restricted in the UK in 199.5, following the 
publication of data showing that trimethoprim alone 
was as effective as cotrimoxazole in the treatment of 
urinary tract infections, and due to concerns about 
hypersensitivity reactions. lg Thus, it was recommended 
that the combination should only be used when there 
was a good reason to prefer it over single-agent 
therapy. l9 Despite a very large decrease in the human 
use of cotrimoxazole (from 3 208 000 prescriptions/year 
in 1991 to 77 000 prescriptions/year in 1999), high-level 
resistance to sulfamethoxazole was as high in 1999 
(46.0%) as it was in 1991 (39.7%) (Figure 2). Investi- 
gation of the susceptibility of sulfamethoxazole-resistant 
isolates and genetic analysis indicated that sulfa- 
methoxazole resistance was linked to resistance to at 
least two other agents of different classes in over 80% 
of isolates, and was due to one or both of two different 
genes. The prevalence of one of these genes increased 
significantly from 1991 to 1999. 
These studies suggest that when resistance to an 
antimicrobial has emerged relatively recently, as with 
erythromycin resistance in S. pyogenes in Finland, or 
is due to clonal spread, as in Iceland, reducing the 
selection pressure by restricting antimicrobial use may 
indeed reduce the prevalence of resistance. However, 
when resistance is well established, with widely dissemi- 
nated resistance genes established in various genetic 
elements and multiple resistance being present, as with 
sulfonamide resistance in the UK, even a very large 
reduction in antimicrobial use on a national scale may 
not decrease the prevalence of resistance within a useful 
time.18 This view is supported by a recent publication 
from Denmark, in which reducing the use of an 
antimicrobial in animals was associated with a decrease 
in the prevalence of resistance to that antimicrobial only 
if it was resistant to a single agent.20 To reduce the 
prevalence of linked or multiple resistance, it was 
necessary to stop using all of the antimicrobials to which 
there was resistance. 
In terms of necessary antimicrobial prescribing, 
bacterial eradication must, therefore, be maximized for 
all the relevant pathogens, including resistant strains. 
Where multiresistant strains are present, failure of anti- 
microbial therapy will select for resistance to all the 
agents to which that strain is resistant. 
THE WAY FORWARD 
It appears that neither existing guidelines nor govern- 
ment directives are wholly adequate to ensure appro- 
priate prescribing in order to fulfill either the individual 
or the collective responsibility for antimicrobial use. 
Ideally, guidelines should be based locally and reflect 
local resistance patterns, drug dosages, drug availability, 
and clinical practice. In addition, the process of 
developing local guidelines can be valuable in itself, 
raising wider issues, highlighting the importance of 
appropriate prescribing, and creating local advocates for 
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implementation. Primarily, however, physicians must 
perceive guidelines as being relevant to their clinical 
practice and experience, and, above all, as improving 
patient outcomes. There is, therefore, a need to develop 
universally applicable principles or strategies in order 
to enable physicians to develop local guidelines for 
appropriate antimicrobial prescribing. 
These issues were addressed in a recent initiative, 
The Consensus Group on Resistance and Prescribing in 
Respiratory Tract Infection, that brought together 
microbiologists and physicians from a range of clinical 
specialties from around the wor1d.l This panel debated 
the current best evidence regarding appropriate use 
of antimicrobials, in order to define areas in which 
agreement could be reached. The objective was not to 
produce another set of guidelines or to direct physicians 
in their everyday practice, but rather to define a set of 
global, general principles for antimicrobial prescribing, 
which would be independent of location and pro- 
fessional specialty. The principles represent the core 
minimum that can be agreed, based on current know- 
ledge: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
It 
The need to identify bacterial infections. 
Optimizing clinical and bacteriologic diagnosis. 
Identifying and acting on ambient resistance levels. 
Targeting bacterial eradication (or maximal 
reduction). 
Optimizing the dose and duration of therapy using 
PD parameters. 
Assessing the true (overall) costs of resistance and 
related treatment failure. 
Incorporating the principles in guidelines and formu- 
laries. 
Identifying and informing end-user gr0ups.l 
is clear that many current practice guidelines meet 
neither these principles nor the evidence-based criteria 
that might strengthen the guideline concept. The most 
effective ways in which the principles can be used to 
guide practice in different situations throughout the 
world need to be determined. 
REFERENCES 
1. Ball P, Baquero F, Cars 0, et al. Antibiotic therapy of 
community respiratory tract infections: strategies for 
optimal outcomes and minimized resistance emergence. 
J Antimicrob Chemother 2002; 49:31-40. 
2. Dagan R, Klugman KP, Craig WA, Baquero E Evidence 
to support the rationale that bacterial eradication in 
respiratory tract infection is an important aim of anti- 
microbial therapy. J Antimicrob Chemother 2001; 47:129- 
140. 
3. Woodhead M. Community-acquired pneumonia guidelines- 
an international comparison: a view from Europe. Chest 
1998; 113(suppl3):183s-187s. 
4. Niederman MS. Community-acquired pneumonia: a North 
American perspective. Chest 1998; 113(suppl3):1798- 182s. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
1.5. 
16. 
17. 
18. 
19. 
20. 
Ball P, Make B. Acute exacerbations of chronic bronchitis: 
an international comparison. Chest 1998; 113(suppl 3): 
199%204s. 
Gleason PP, Kapoor WN, Stone RA, et al. Medical 
outcomes and antimicrobial costs with the use of the 
American Thoracic Society guidelines for outpatients with 
community-acquired pneumonia. JAMA 1997; 278:32-39. 
Niederman MS, Bass JB, Campbell GD, et al. American 
Thoracic Society guidelines for the initial management 
of adults with community-acquired pneumonia: diagnosis, 
assessment of severity, and initial antimicrobial therapy. 
Am J Respir Crit Care Med 1993; 148:1418-1426. 
Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial 
selection for hospitalized patients with presumed com- 
munity-acquired pneumonia: a survey of nonteaching US 
community hospitals. Ann Pharmacother 2000; 34:446-452. 
Marras TK, Chan CK. Use of guidelines in treating com- 
munity-acquired pneumonia. Chest 1998; 113:1689-1694. 
Mandell LA, Niederman M, the Canadian Community 
Acquired Pneumonia Consensus Conference Group. Anti- 
microbial treatment of community acquired pneumonia in 
adults: a conference report. Can J Infect Dis 1993; 4:25’-28. 
American Thoracic Society. Guidelines for the manage- 
ment of adults with community-acquired pneumonia. 
Diagnosis, assessment of severity, antimicrobial therapy, 
and prevention. Am J Respir Crit Care Med 2001; 163: 
1730-1754. 
Beilby J, Marley J, Walker D, Chamberlain N, Burke M, 
the FIESTA Study Group. Effect of changes in antibiotic 
prescribing on patient outcomes in a community setting: a 
natural experiment in Australia. Clin Infect Dis 2002; 
34:55-64. 
Collignon PJ, Turnidge JD. Antibiotic resistance in 
Streptococcus pneurrzoniae. Med J Aust 2000; 173:S58-S64. 
Cars 0. Steering an appropriate course: principles to guide 
antibiotic choices. Respir Med 2001; 95(suppl A):S20-S25. 
Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect 
of changes in the consumption of macrolide antibiotics 
on erythromycin resistance in group A streptococci in 
Finland. N Engl J Med 1997; 337:441-446. 
Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir 
G, Molstad S, Gudmundsson S. Do antimicrobials increase 
the carriage rate of penicillin resistant pneumococci in 
children? Cross-sectional prevaIence study. BMJ 1996; 
313:387-391. 
Kristinsson KG, Hjalmarsdottir MA, Gudnason TH. 
Continued decline in the incidence of penicillin non- 
susceptible pneumococci in Iceland [Abstract C22]. In: 
Program and abstracts of the 38th Interscience Conference 
on Antimicrobial Agents and Chemotherapy, San Diego, 
USA. Washington, DC: American Society for Microbiology, 
1998:74. 
Enne V, Livermore DM, Stephens P, Hall LMC. 
Persistence of sulphonamide resistance in Escherichia coli 
in the UK despite national prescribing restriction. Lancet 
2001; 357:1325-1328 [Correction in Lancet 2001; 357:1890]. 
Anon. Co-trimoxazole use restricted. Drug Ther Bull 1995; 
33:92-93. 
Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, 
Hendriksen RS, Bager E Effect of abolishment of the use 
of antimicrobial agents for growth promotion on occur- 
rence of antimicrobial resistance in fecal enterococci from 
food animals in Denmark. Antimicrob Agents Chemother 
2001; 45:2054-2059. 
